Sulfaminoheparosans (SAH; also designated as bioheparins) are the result of attempts to produce heparin-like agents to compensate for the decreasing availability of conventional heparin sources. Casu and coworkers described the development of a series of heparin-like products through regioselective sulfation of the capsular polysaccharide from Escherichia coli K5 (1). The polymeric backbone known as N-acetyl heparosan provides a novel starting material to develop semi-synthetic heparin-like molecules. To accomplish this, the bacterial polysaccharide is first converted to sulfaminoheparosan by deacetylation followed by N-sulfation. Enzymatic epimerization of the glucuronic acid moiety and
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controlled O-sulfation of this product results in the generation of a series of novel heparin-like oligosaccharide mixtures with varying Osulfation patterns and anticoagulant activities. This sulfated oligosaccharide also shows varying degrees of binding to antithrombin (AT) due to the presence of 3,0-sulfated glucosamine. Thus, using these semi-synthetic approaches, anticoagulants with structural identities, distinct from heparin, yet exhibiting similar interactions with heparin co-factor-II (HC-II) and AT can be developed. These bacterial polysaccharide derivatives interact with AT and promote its anticoagulant action in a manner similar to that of heparin (2) . Bioheparins, because of their charge density also share other biologic activities with heparin including endogenous release of mediators such as tissue factor pathway inhibitor (TFPI), modulation of adhesion molecules, interaction with endothelial cells and anti-inflammatory effects. It was also demonstrated that the highly N,Osulfated derivatives of K5 polysaccharides act as an antagonists of fibroblast growth factor 2 (FGF2) with antiangiogenic activity (3). Like LMWHs, there are LMW-K5 derivatives, which are FGF antagonists. A series of these SAHs, with different degrees and distribution of sulfates, inhibit B16-BL6 melanoma lung colonies (4) . Our recent studies have shown that a LMW SAH fraction has similar biochemical and pharmacologic profiles as a LMWH, tinzaparin (5) . It has been also shown that the bioheparins, such as heparin (UFH) and tinzaparin, are readily neutralized by protamine sulfate (6) . Based on these biochemical and pharmacologic characteristics of bioheparins, it was hypothesized that, like heparins, these compounds inhibit the tissue factor (TF)-mediated activation of platelets. The purpose of this study was to determine the comparative effects of heparins (unfractionated heparin and tinzaparin) and various fractions of bioheparins with different molecular weights (20, 9, 7, and 6 kDa) on the TF-induced activation of platelets using whole blood flow cytometry.
MATERIALS AND METHODS

Materials
Four different K5 derivative fractions with different molecular weights (Bio-20 kDa, Bio-9 kDa, Bio-7 kDa, and Bio-6 kDa) were used in this study. They were obtained in the form of whitish powder and stored at room temperature. All of the bioheparins were provided by Inalco (Milan, Italy). Unfractionated heparin (Lot RB 21055, Sanofi, Choay Institute, Paris, France) and tinzaparin (Leo Pharmaceutical, Copenhagen, Denmark) were also used in this study for comparative purposes. Both UFH and tinzaparin were also obtained as white powders and were stored at room temperature.
Tissue factor (TF), thromboplastin C Plus was obtained from Dade Behring Inc. (Newark, DE). Fluorescein isothiocyanate (FITC)-labeled anti-CD61 and phycoerythrin (PE)-labeled anti-CD62 antibodies were obtained from Becton-Dickinson (San Jose, CA).
Method
Preparation of samples Native whole blood was freshly drawn into polypropylene syringes using a double syringe technique from normal healthy volunteers (n = 5) who were medication free (clopidogrel, aspirin) for at least 10 days. The protocol to draw the blood was approved by Institutional Review Board (IRB), Loyola University Medical Center.
The agents were prepared in saline and tested at final concentrations of 100 and 10 µg/mL. Two hundred forty microliters of fresh whole blood was incubated with 30 µL of each test agent or vehicle for 120 seconds at 37°C. Following the incubation, 30 µL of TF (reconstituted with 10 mL of deionized water and diluted 1:20 in 0.025 M CaCl 2 ) was added and the incubation was continued for another 120 seconds. Fifty microliters of activated blood was fixed in 1 mL of 1% paraformaldehyde for 30 minutes at 4°C. The samples were centrifuged at 350xg for 10 minutes and the supernatant was removed. The cells were resuspended in 500 µL of calcium free Tyrode's buffer and 100 µL of these samples were incubated with 6.5 µL CD61 FITC and 6.5 µL CD62PE for at least 45 minutes at room temperature in the dark.
Data analysis
This study was performed using the EPICS XL flow cytometer (Beckman Coulter Inc., Miami, FL) and the data was analyzed using WinMDI 2.8 software. The flow cytometric settings were aligned and optimized by running flow check beads (Beckman Coulter Inc, Fullerton, CA) before the samples were run on the instrument.
A minimum of 10,000 CD61 (+) events (platelets) were collected for each sample. Electronic gates were set on the forward scatter vs. CD61 fluorescence density plot to separate single platelets (R1) from platelet aggregates (R2) and also to exclude platelet-leukocyte aggregates as well as platelet-erythrocyte aggregates as seen in Fig. 1 (7,8) .
The fraction of single platelets expressing CD62 was determined using a marker set to an arbitrary value of 2% using the saline control (10) . The platelet activation was measured in terms of the extent of platelet aggregation (Fig.  1 ) and the percent of the unaggregated platelet population that was positive for P-selectin.
Statistical Analysis
The data are presented as mean ± standard error of the mean (SEM) of five individual experiments. Analysis of variance (One-way ANOVA, followed by Newman-Keul's test) and paired t-test were performed to determine statistical significance (p < .05).
RESULTS
Fig. 2 shows the effect of various bioheparin
fractions, UFH and tinzaparin, on TF-induced platelet aggregation. The aggregation of platelets is significantly (p < .001, one-way ANOVA followed by Newman-Keul's test) decreased in the presence of bioheparin fractions and heparins at 100 µg/mL, in comparison to TF alone group (zero). The extent of inhibition is almost same with all the agents. However, the effects of these agents are not strong and did not significantly differ from control group (zero) at the lower concentration of 10 µg/mL. There was a significant (p < .05, paired t-test) concentration dependency noted with all the agents except bio-20 kDa and bio-9 kDa on the inhibition of platelet aggregation.
As depicted in Fig. 3 , the expression of Pselectin is blunted significantly (p < .001, oneway ANOVA followed by Newman-Keul's test) with all the agents at 100 µg/mL. At a lower concentration of 10 µg/mL, the inhibition of Pselectin expression in presence of these agents decreased to some extent but not significantly, when compared to their effects at 100 µg/mL, except for tinzaparin (p < .03, paired t-test). The inhibitory effects are still significant (p < .05, One-way ANOVA, followed by Newman-Keul's test) even at lower concentration except for bio-20 kDa in comparison to control groups (saline + TF). The percentage of platelets expressing Pselectin correlates with the percent aggregation of platelets. All the agents exhibited almost similar inhibitory effects. However bio-20 kDa at the concentration of 10 µg/mL has somewhat weaker effects than the other bioheparin fractions and heparins.
All of these agents were also tested for their direct interactions with the platelets. Fig. 4A shows the percent aggregation of platelets when incubated with all the agents at a final concentration of 100 µg/mL. The percent aggregation of platelets with these agents did not significantly differ from control group. The results for P-selectin expression correlate with the percent aggregation of platelets for bio-6 kDa, UFH and tinzaparin. As can be seen in Fig.  4B , bio-20, bio-9 and bio-7 kDa significantly (p < .05, one-way ANOVA followed by Newman-Keul's test) inhibit P-selectin expression in comparison to control group (saline with TF).
However, the effects of bio-6 kDa, UFH and tinzaparin did not differ from saline control significantly.
DISCUSSION
Tissue factor plays a major role in the mediation of thrombogenesis in both the arterial and venous system (9, 10) . Anticoagulant drugs such as heparin and bioheparins by virtue of their ability to release endogenous TFPI are FIG. 4. Direct interactions of bioheparin fractions and heparins with platelets. As can be seen in (A), none of these agents significantly, directly activated the platelets in comparison to control group (saline). As shown in (B), the percent population of platelets positive for P-selectin with bio-20 kDa, bio-9 kDa and bio-7 kDa is significantly (*p < .05, one-way ANOVA followed by Newman-Keul's test) lesser than control group (saline). However, with bio-6 kDa, UFH and tinzaparin there was no significant difference from saline control. Data represent mean ± SEM of n = 5.
capable of inhibiting the effect of this thrombogenic mediator on the generation of thrombin and factor X. Additionally these anticoagulants are capable of interacting with serpins to inhibit serine proteases such as factor Xa and thrombin.
In the current studies, a whole blood system is used to demonstrate the inhibitory effects of heparins and bioheparins on platelet activation mediated by exogenous tissue factor. This experimental approach provided a direct measure of the modulatory actions of heparins and bioheparins as measured by flow cytometry. The activation of platelets was quantitated by measuring the extent of platelet aggregation and the expression of P-selectin.
Bioheparins ranging from 6 to 20 kDa (mean molecular weight) exhibited a comparable degree of inhibition which was similar to those observed with UFH and LMWH tinzaparin. All of the agents strongly inhibited (approximately 40%) platelet aggregation at 100 µg/mL. The inhibitory effects were weaker (22%) at lower concentration of 10 µg/mL as shown in Table 1 . The bioheparins did not exhibit any molecular weight dependence when compared at equigravimetric amounts. Both the heparins and bioheparins also produced inhibition of tissue factor-mediated P-selectin expression to a similar extent. No significant differences between these six agents were observed at concentration of 100 and 10 µg/mL in this parameter.
The current studies reported here were carried out at gravimetric levels. However, because these agents exhibit wide differences in the molecular weight and biologic activities it is conceivable that in biologically standardized studies differences may be noted.
The exact mechanism by which these agents are capable of inhibiting TF-mediated platelet activation is not clear at this time. However, because thrombin is a potent activator of platelets, it is likely that the observed inhibition of TF-mediated activation of platelets is through the inhibition of this enzyme by the agents studied. All of these agents exhibit anti-thrombin effects, which are mediated via HC-II or AT. Therefore additional studies on affinity fractions obtained from HC-II and AT fractionation will be useful in elucidating these mechanisms. Regardless of the limited information on the mechanisms of the inhibitory effects, it is logical to propose that modulation of TF-mediated platelet activation by heparins and bioheparins contribute to their therapeutic actions. Heparins and bioheparins produce a comparable inhibition of TF-induced platelet aggregation. Data represent mean ± SEM of five individual experiments.
